Abbott Laboratoriesvs.Quest Diagnostics
ABT vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 7.1× larger than Quest Diagnostics by market cap; Quest Diagnostics trades at the lower P/E (22.6 vs 26.1); year to date, Quest Diagnostics leads (+19.5% vs −25.0%).
Side by side
| ABT | DGX | |
|---|---|---|
| Market cap | $164B | $23.1B |
| Price | $93.93 | $207.44 |
| Today | −0.5% | −0.3% |
| Return YTD | −25.0% | +19.5% |
| Return 1Y | −29.7% | +21.0% |
| P/E | 26.1 | 22.6 |
| P/S | 3.6 | 2.1 |
| P/B | 3.1 | 3.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Abbott LaboratoriesABT
American healthcare group with four divisions: diagnostics, medical devices (including glucose monitoring), nutrition and generics.
Full ABT profile →Quest DiagnosticsDGX
Nationwide clinical laboratory network for routine and advanced diagnostics.
Full DGX profile →More comparisons in Diagnostics
See where ABT and DGX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →